Abstract
Abstract
Background
Uruguay is widely known as a pioneer country regarding cannabis regulation policies, as it was the first state to regulate the cannabis market for both recreational and medicinal purposes in 2013. However, not all aspects of the regulation have moved forward at the same speed. Medicinal uses keep facing several challenges that undermine patients’ effective access to treatments and products. What are those persistent challenges for the medicinal cannabis policy in Uruguay? This paper aims to describe and understand the current state of medicinal cannabis in the country and identify the most critical challenges and conflicting forces for its proper implementation.
Methods
To do so, we conduct twelve in-depth interviews with key informants, including governments officials, activists, entrepreneurs, researchers, and doctors. These interviews are complemented with information from the congressional committees’ public records and other documentary sources.
Results
This research shows that the legal framework was thought to assure quality products over access. The main challenges of medicinal cannabis in Uruguay are related to three issues: (i) the timid development of the industry, (ii) a limited and expensive supply, and (iii) the emergence of an informal productive sector.
Conclusions
The political decisions regarding medicinal cannabis made in the last seven years have derived from a halfway policy that fails to guarantee patient access or promote the growth of a vibrant national industry. Positively, the several actors involved are aware of the extent of these challenges and new decisions have been made to overcome them, meaning that monitoring the future of the policy is very much needed.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmacology,Health (social science)
Reference37 articles.
1. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products-regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.
2. Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Políticas y prácticas sobre cannabis medicinal en el mundo. México Unido Contra La Delincuencia. 2018;33:1–32.
3. Asamblea General. Ley 19.172. Regulación y control del cannabis. 2013. D.O. N$$^{\circ }$$ 28.878. Retrieved from: https://www.impo.com.uy/diariooficial/2014/01/07/documentos.pdf.
4. Belackova V, Shanahan M, Ritter A. Mapping regulatory models for medicinal cannabis: a matrix of options. Aust Health Rev. 2017;42(4):403–11.
5. Calderón Vallejo GA, Pareja Hincapié LM, Caicedo Cano C, Chica Ríos RA. Regulación del uso de marihuana en Colombia con fines medicinales. Hacia Promoción Salud. 2017;22(1):43–55.